Enasidenib Mesylate
CAS 1650550-18-0 2 FDA-DMF suppliersSmall Molecule
Overview
Enasidenib Mesylate is an inhibitor of the mutant isocitrate dehydrogenase 2 (IDH2) enzyme. It is used in the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) who harbor IDH2 mutations.
Therapeutic areas
OncologyHematology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.